Geron Analyst Ratings
Critical Insights From Geron Analyst Ratings: What You Need To Know
Geron Analyst Ratings
Wedbush Raises Geron's Price Target to $8 From $7, Outperform Rating Maintained
Geron Analyst Ratings
Wedbush Adjusts Geron's Price Target to $7 From $6, Keeps Outperform Rating
Geron Analyst Ratings
Buy Rating Affirmed for Geron Amid Positive Imetelstat Launch Prospects and Strong Financials
Analysts Conflicted on These Healthcare Names: Dyne Therapeutics (DYN) and Geron (GERN)
Geron Analyst Ratings
Geron Analyst Ratings
Buy Rating Affirmed for Geron Following Insightful Leadership Discussion and Promising Drug Development Progress
Analysts Offer Insights on Healthcare Companies: Carl Zeiss Meditec (GB:0DHC), Geron (GERN) and Zur Rose Group AG (Six Swiss: CH:DOCM)
Geron Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Geron (GERN)
Geron Analyst Ratings
Stifel Nicolaus Reaffirms Their Buy Rating on Geron (GERN)
Geron Analyst Ratings
Geron Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), ACELYRIN, INC. (SLRN) and Geron (GERN)